Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 4/20 | 0.63 |
| ▸ | CD44 | P16070 | 1/20 | 0.63 |
| ▸ | MAOB | P27338 | 1/20 | 0.63 |
| ▸ | HTR2C | P28335 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL2586959 | 0.95 | PNMT (0.66) | PNMTCD44MAOBHTR2CTSHR | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL28542017 | 0.90 | PNMT (0.73) | PNMTCD44MAOBHTR2CALOX15 | |
| SCHEMBL8144398 | 0.88 | CD44 (0.46) | PNMTCD44MAOBHTR2CTSHR | |
| SCHEMBL28370551 | 0.86 | TSHR (0.54) | PNMTCD44MAOBHTR2CTSHR | |
| SCHEMBL29373532 | 0.86 | TSHR (0.52) | PNMTCD44MAOBHTR2CTSHR | |
| SCHEMBL24119 | 0.86 | TSHR (0.52) | PNMTCD44MAOBHTR2CTSHR | |
| SCHEMBL28370547 | 0.86 | TSHR (0.52) | PNMTCD44MAOBHTR2CTSHR | |
| SCHEMBL23555059 | 0.84 | HTR2C (0.58) | PNMTCD44MAOBHTR2CTSHR | |
| SCHEMBL2425535 | 0.84 | TSHR (0.50) | HTR2CTSHRALOX15HSD17B10MAPT | |
| SCHEMBL19996347 | 0.84 | TSHR (0.50) | HTR2CTSHRALOX15HSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875631-B2 | e.g.1-(3,5-dichlorophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline; to prevent and/or treat cancer and other abnormal cell growth, and metabolic as well as blood vessel proliferate disorders, in which uncontrolled expression of insulin-like growth factor-1 receptor is observed | ANALYTECON S.A. (CH) | 2011-01-25 | — | — | US | disclosed |
| US-20070129399-A1 | Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors | ANALYTECON S.A. (CH) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129399-A1 | Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors | IGF1R, INSR, GPR119 | PNMT 2706/4885CD44 4517/4885MAOB 1990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.